Showing results (31-40 of 104) with videos related to

Sort By:
Pageof 11
Arzneimittel-Forschung|January 1, 1979
The efficacy of four respiratory analeptics on healthy young men in a CO2 rebreathing experimentK J Wiessmann, V W Steinijans, D Brossmann
Arzneimittel-Forschung|August 1, 1988
Pharmacokinetic profile of a new sustained-release theophylline pellet formulation for once-daily evening administrationV W Steinijans, R Sauter, A Böhm, et al.
The European Respiratory Journal|September 1, 1992
Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthmaT Brunnée, R Engelstätter, V W Steinijans, et al.
Arzneimittel-Forschung|August 1, 1988
Theophylline therapeutic drug monitoring in the case of a new sustained-release pellet formulation for once-daily evening administrationV W Steinijans, H Trautmann, R Sauter, et al.
Arzneimittel-Forschung|August 1, 1988
Feasibility of in-vitro/in-vivo correlation in the case of a new sustained-release theophylline pellet formulationR Dietrich, R Brausse, G Benedikt, et al.
Respiration; International Review of Thoracic Diseases|January 1, 1980
[Normal ranges of the mean in- and expiratory airways resistance and gas-dynamic breathing efficiency (author's transl)]K H Kieft, V W Steinijans, K J Wiessmann
Chronobiology International|January 1, 1987
Theophylline steady-state pharmacokinetics: recent concepts and their application in chronotherapy of reactive airway diseasesV W Steinijans, H Trautmann, E Johnson, et al.
International Journal of Clinical Pharmacology, Therapy, and Toxicology|January 1, 1992
Lack of pharmacokinetic interaction as an equivalence problemV W Steinijans, M Hartmann, R Huber, et al.
European Journal of Clinical Pharmacology|January 1, 1987
Absolute bioavailability of theophylline from a sustained-release formulation using different intravenous reference infusionsV W Steinijans, H U Schulz, A Böhm, et al.
International Journal of Clinical Pharmacology and Therapeutics|July 1, 1994
Choice of characteristics and their bioequivalence ranges for the comparison of absorption rates of immediate-release drug formulationsR Schall, H G Luus, V W Steinijans, et al.
Pageof 11